Higher semaglutide Dose Shows promise for Meaningful Weight Loss in Clinical Trials

A new study reveals that a higher dose of semaglutide leads to greater weight reduction and improved health outcomes for adults with obesity, including those with type 2 diabetes.

New research indicates that a 7.2 mg weekly dose of semaglutide can significantly enhance weight loss and improve related health markers in adults with obesity, including those with type 2 diabetes (T2D). The findings come from two large-scale, international phase 3 clinical trials.

Published in The Lancet Diabetes & Endocrinology journal, the study suggests that this higher dose of semaglutide presents a potentially more effective treatment option for individuals with obesity, including those with T2D, who haven’t achieved sufficient weight loss through existing methods.

The STEP UP and STEP UP T2D clinical trials investigated the safety and efficacy of increasing the semaglutide dose from the currently approved 2.4 mg to 7.2 mg. Participants were randomly assigned to receive either the 7.2 mg dose, the 2.4 mg dose, or a placebo over a 72-week period. All participants received lifestyle interventions, including dietary counseling and recommendations for increased physical activity.

Significant weight Loss Achieved

In participants without diabetes, the 7.2 mg semaglutide dose resulted in an average weight loss of nearly 19%, exceeding the 16% loss observed with the 2.4 mg dose and the 4% loss with the placebo. Almost half of the participants in the higher-dose group experienced a 20% or greater reduction in body weight, with approximately one-third losing at least 25%. Participants also showed improvements in waist circumference, blood pressure, blood sugar, and cholesterol levels.

Similarly, in adults with obesity and T2D, the 7.2 mg dose lead to an average weight loss of 13%, compared to 10% with the 2.4 mg dose and 3.9% with the placebo. Significant reductions in blood sugar levels and waist size were also observed.

Safety and Tolerability

Both trials indicated that the higher semaglutide dose was safe and generally well-tolerated. The most common side effects were gastrointestinal issues such as nausea and diarrhea, as well as some sensory symptoms like tingling. Though, these side effects were generally manageable, resolved over time, and did not lead to a high rate of trial dropouts. No increase in serious adverse events or severe hypoglycemia was observed with the higher dose.

Potential Impact

Researchers suggest that by providing greater weight reduction and metabolic benefits while maintaining a favorable safety profile,the higher semaglutide dose could help more individuals achieve their health goals and reduce the global burden of obesity-related complications. However, they emphasize the need for further research to fully understand the long-term benefits and risks.

Explainer: Semaglutide and weight Loss

Semaglutide is a medication that mimics a naturally occurring hormone in the body called glucagon-like peptide-1 (GLP-1). GLP-1 plays a role in regulating appetite and blood sugar levels. By mimicking this hormone, semaglutide can definitely help to reduce appetite, leading to decreased food intake and subsequent weight loss. It also helps to improve blood sugar control, making it a valuable treatment option for individuals with type 2 diabetes. Semaglutide is administered via injection and is used in conjunction with lifestyle modifications such as diet and exercise.

More information: Daily steps and health outcomes in adults: a systematic review and dose-response meta-analysis, The Lancet Diabetes & Endocrinology (2025). DOI: 10.1016/S2213-8587(25)00226-8